Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, James A.R., Wilkinson, David, Holmes, Clive, Steart, Phil, Markham, Hannah, Weller, Roy O.·2003·Nature Medicine
DOI 10.1038/nm840

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.
    Pritam Das, Lisa A. Smithson, Robert W Price, Vallie M. Holloway, Yona Levites, Paramita Chakrabarty, Todd Eliot Golde · 2006 · Journal of Neuroinflammation
  2. Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
    Syed Ehtaishamul Haque, Ashif Iqubal, Mohammad Kashif Iqubal, Syed Abul Fazal, Faheem Hyder Pottoo · 2021 · Current Molecular Pharmacology
  3. Amyloid Imaging with PET in Alzheimer’s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects
    William Edward Klunk, Chester A. Mathis, Julie C. Price, Steven Trent DeKosky, Brian J. Lopresti, Nicholas D. Tsopelas, Judith A. Saxton, Robert D. Nebes · 2009 · Springer eBooks
  4. Current State of Immunotherapy for Alzheimer’s Disease
    Norman R. Relkin · 2008 · CNS Spectrums
  5. Case 22-2010
    Steven Mark Greenberg, Otto Rapalino, Matthew P. Frosch · 2010 · New England Journal of Medicine
  6. Therapeutic potential of oxidant mechanisms in Alzheimer’s disease
    Paula Isabel Moreira, Mark A. Smith, Xiongwei Zhu, Maria S. Santos, Catarina Resende Oliveira, George L. Perry · 2004 · Expert Review of Neurotherapeutics
  7. Immunity and neuronal repair in the progression of Alzheimer’s disease: A brief overview
    Rona Baron, Idan Harpaz, Anna Nemirovsky, Hagit Cohen, Alon Monsonego · 2006 · Experimental Gerontology
  8. Inflammatory disorders of the central nervous system
    Gavin Giovannoni, David Baker · 2003 · Current Opinion in Neurology
  9. Vaccines for conformational disorders
    Martin J. Sadowski, Thomas Wısnıewskı · 2004 · Expert Review of Vaccines
  10. Angiotensin-Receptor Blockers, Hypertension and Alzheimer Disease
    Takayuki Katayama, Naoyuki Hasebe · 2012 · Circulation Journal
  11. Adaptive immunity in the neuroinflammation of Alzheimer’s disease
    Hanchen Liu, Yun Chen, Jing Zhang, Xiaochun Chen · 2025 · Chinese Medical Journal
  12. Effects of a 15-amino-acid isoform of amyloid- β expressed by silkworm pupae on B6C3-Tg Alzheimer’s disease transgenic mice
    Si Li, Yangyang Jin, Chi Chiu Wang, Jian Chen, Wei Yu, Yongfeng Jin, Zhengbing Lv · 2019 · Journal of Biotechnology
  13. Vascular Considerations for Amyloid Immunotherapy
    Kate E. Foley, Donna M. Wilcock · 2022 · Current Neurology and Neuroscience Reports
  14. Postmortem findings in a patient with cerebral amyloid angiopathy actively treated with corticosteroid
    Kazuko Machida, Ayako Tsuchiya‐Suzuki, Kenji Sano, Kunimasa Arima, Yuko Saito, Fuyuki Kametani, Shu‐ichi Ikeda · 2012 · Amyloid
  15. Complementary Distributions of Amyloid-β and Neprilysin in the Brains of Dogs and Cats
    Y. Takeuchi, Koji Uetsuka, M. Murayama, Fumio Kikuta, Akihiko Takashima, K. Doi, Hiroyuki Nakayama · 2008 · Veterinary Pathology
  16. Drug Targets from Genetics: Alpha-Synuclein
    Karin M. Danzer, Pamela J. McLean · 2011 · CNS & Neurological Disorders - Drug Targets
  17. Development of vaccination approaches for the treatment of neurological diseases
    Howard J. Federoff · 2009 · The Journal of Comparative Neurology
  18. ¿Es factible la vacunación contra la encefalopatía espongiforme transmisible?
    Thomas Wısnıewskı, Jose Alejandro Chabalgoity, Fernando Goñi · 2007 · Scientific and Technical Review (World Organisation for Animal Health)
  19. Hereditary and sporadic beta-amyloidoses
    Giuseppe Di Fede · 2013 · Frontiers in bioscience
  20. Utilizing Advanced Imaging and Surrogate Markers Across the Spectrum of Alzheimer's Disease
    Mark A. Mintun · 2005 · CNS Spectrums
  21. Clearing Tau Pathology with Aβ Immunotherapy—Reversible and Irreversible Stages Revealed
    Michael L. Hutton, Eileen M. McGowan · 2004 · Neuron
  22. Amplicons as Vaccine Vectors
    Kathlyn Santos, Cindy M. Duke, Stephen Dewhurst · 2006 · Current Gene Therapy
  23. Metal Chelation Therapy for Alzheimer Disease
    Roger N. Rosenberg · 2003 · Archives of Neurology
  24. Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
    Ellis S. van Etten, Simin Mahinrad, Joshua D. Grill, Stephen Salloway, Alireza Atri, Petrice M. Cogswell, Tammie L.S. Benzinger, Takeshi Iwatsubo, Costantino Iadecola, Cynthia Ann Lemere et al. · 2026 · Alzheimer s & Dementia
  25. Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?
    Yoh Matsumoto, Kuniko Kohyama · 2015 · ImmunoTargets and Therapy
  26. Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1–43/IL-10 cDNA
    Hideo Hara, Akihiro Mouri, Yoshikazu Yonemitsu, Toshitaka Nabeshima, Takeshi Tabira · 2011 · Vaccine
  27. Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease
    Jinghong Kou, Min Song, Abhinandan Pattanayak, Jeong Eun Lim, Junling Yang, Dongfeng Cao, Ling Li, Ken‐ichiro Fukuchi · 2012 · Journal of Neuroimmunology
  28. Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
    Filippo Caraci, Paolo Bosco, Gian Marco Leggio, Michele Malaguarnera, Filippo Drago, Claudio Bucolo, Salvatore Salomone · 2013 · Current Topics in Medicinal Chemistry
  29. Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
    Stacie C. Weninger, Bjørn Sperling, Robert Alexander, Magnus Ivarsson, Fiona M. Menzies, Peter Powchik, Christopher J. Weber, C. Anthony Altar, Ronald G. Crystal, Stephen J. Haggarty et al. · 2020 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  30. Immunosenescence of brain accelerates Alzheimer’s disease progression
    Hou-Yu Chen, Yan Gang Zhao, Yongzhi Xie · 2022 · Reviews in the Neurosciences
  31. Immunization with a new DNA vaccine for Alzheimer's disease elicited Th2 immune response in BALB/c mice by in vivo electroporation
    Xiaona Xing, Sha Sha, Yu Li, Lixia Zong, Tongzi Jiang, Yunpeng Cao · 2011 · Journal of the Neurological Sciences
  32. Disease Modifying Therapies for Alzheimer's Disease Targeting AβOligomers: Implications for Therapeutic Mechanisms
    Etsuro Matsubara, Ayumi Takamura, Yasuhide Okamoto, Hideto Oono, Takashi Nakata, Yasuhito Wakasaya, Takeshi Kawarabayashi, Mikio Shoji · 2013 · BioMed Research International
  33. Immunotherapy for Alzheimer’s Disease: DNA- and Protein-Based Epitope Vaccines
    Hayk Davtyan, Irina Petrushina, Anahit Ghochikyan · 2014 · Methods in molecular biology
  34. Evaluation of a DNA Aβ 42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ 42 Trimer
    Doris Lambracht‐Washington, Min Fu, Mary Wight‐Carter, Matthew S. Riegel, Roger N. Rosenberg · 2017 · Journal of Alzheimer s Disease
  35. Structural Optimization of Foldamer-Dendrimer Conjugates as Multivalent Agents against the Toxic Effects of Amyloid Beta Oligomers
    Éva Bartus, Gábor Olajos, Ildikó Schuster, Zsolt Bozsó, Mária A. Deli, Szilvia Veszelka, Fruzsina R. Walter, Zsolt Datki, Zsolt Szakonyi, Tamás A. Martinek et al. · 2018 · Molecules
  36. Effects of Microglial Cytokines on Alzheimer’s Disease-Related Phenomena
    Yan Ji, Xiaowan Wang, Colin H. Kalicki, Blaise W. Menta, Megan Baumgardner, Scott J. Koppel, Ian W. Weidling, Judit Perez Ortiz, Heather Wilkins, Russell Howard Swerdlow · 2019 · Journal of Alzheimer s Disease
  37. Subspace Network
    Mengying Sun, İnci M. Baytaş, Liang Zhan, Zhangyang Wang, Jiayu Zhou · 2018 · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD)
  38. Development and Characterization of a TAPIR-Like Mouse Monoclonal Antibody to Amyloid-β
    Jun Wang, Hideo Hara, Takao Makifuchi, Takeshi Tabira · 2008 · Journal of Alzheimer s Disease
  39. Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice
    Neelima B. Chauhan, Francesca Davis, Chun Xiao · 2011 · Vaccine
  40. Alzheimer’s disease: from molecular pathogenesis to innovative therapies
    Elio Angelo Scarpini, Filippo Maria Cogiamanian · 2003 · Expert Review of Neurotherapeutics
  41. Adoptive Transfer of T Lymphocytes Sensitized against the Prion Protein Attenuates Prion Invasion in Scrapie-Infected Mice
    Pauline Gourdain, Sylvie Grégoire, Saci Iken, Véronique S. Bachy, Gauthier Dorban, Thomas Chaigneau, Hanna Dêbiec, Anne‐Sophie Bergot, Isabelle Renault, Pièrre Aucouturier et al. · 2009 · The Journal of Immunology
  42. ACAID as a potential therapeutic approach to modulate inflammation in neurodegenerative diseases
    Diana Toscano-Tejeida, Antonio Ibarra, Bryan Víctor Phillips-Farfán, A.L. Fuentes-Farías, Esperanza Meléndez‐Herrera · 2016 · Medical Hypotheses
  43. Ultra-Early Phase pathologies of Alzheimer’s disease and other neurodegenerative diseases
    Hitoshi Okazawa · 2017 · Proceedings of the Japan Academy Series B
  44. Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage
    A.D. Kay, Stephen Day, James A. R. Nicoll, Chris J. Packard, MURIEL J. CASLAKE · 2003 · Atherosclerosis
  45. Deglycosylation of anti-ß amyloid antibodies inhibits microglia activation in BV-2 cellular model
    Sabina Rebe, Beka Solomon · 2005 · American Journal of Alzheimer s Disease & Other Dementias®
  46. Progress towards a vaccine for Huntington's disease
    Ruth Luthi‐Carter · 2003 · Molecular Therapy
  47. Aberrant protein structure and diseases of the brain
    Alfred T. Welzel, Dominic M. Walsh · 2010 · Irish Journal of Medical Science (1971 -)
  48. Novel Pharmacotherapies for Alzheimer's Disease
    Seol‐Heui Han · 2009 · Journal of Korean Medical Association
  49. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques
    Sandrine Benhamron, Lea Rozenstein‐Tsalkovich, Keren Nitzan, Oded Abramsky, Hanna Rosenmann · 2018 · Experimental Neurology
  50. Alzheimer's disease: overview
    David F. Tang‐Wai, Keith A. Josephs, Ronald Carl Petersen · 2005 · Cambridge University Press eBooks
  51. Maladie d'Alzheimer : prendre en compte les facteurs de risque et pathologies cardiovasculaires
    Valéry Antoine, Anne‐Sophie Rigaud · 2005 · La Revue de Médecine Interne
  52. A Computational Positron Emission Tomography Simulation Model for Imaging ?-Amyloid in Mice
    Melvin K. Simmons, Ravindra M. Manjeshwar, Eric D. Agdeppa, Robert M. Mattheyses, Thomas R. Kiehl, Michael Montalto · 2004 · Molecular Imaging and Biology
  53. The genetics of the amyloidoses: interactions with immunity and inflammation
    Joel N. Buxbaum · 2006 · Genes and Immunity
  54. A novel antibody targeting sequence 31–35 in amyloid β protein attenuates Alzheimer's disease‐related neuronal damage
    Li Cheng, Jun Zhang, Xinyi Li, Yuan Li, Yanfang Pan, Xiaorong Chen, Tianming Gao, Jian‐Tian Qiao, Jin‐Shun Qi · 2016 · Hippocampus
  55. Assessment of the Bioactivity of Antibodies against β-Amyloid Peptide in vitro and in vivo
    M. Hasan Mohajeri, Meret N.M. Gaugler, Julia Martinez, Jay Tracy, Hong Li, Arames Crameri, Katrin Kuehnle, Marc Axel Wollmer, Roger M. Nitsch · 2004 · Neurodegenerative Diseases
  56. Gene-environment interplay in neurogenesis and neurodegeneration
    Tomás Palomo, Trevor Archer, Richard J Beninger, Richard M. Kostrzewa · 2004 · Neurotoxicity Research
  57. Pimp my antibody
    Erika Check · 2007 · Nature
  58. Immunization therapy for Alzheimer disease?
    David Alan Bennett, David M. Holtzman · 2005 · Neurology
  59. Reducing Available Soluble β-Amyloid Prevents Progression of Cerebral Amyloid Angiopathy in Transgenic Mice
    Julia L. Gregory, Claudia M. Prada, Sara Fine, Mónica Garcı́a-Alloza, Rebecca A. Betensky, Michal Arbel‐Ornath, Steven Mark Greenberg, Brian J. Bacskai, Matthew P. Frosch · 2012 · Journal of Neuropathology & Experimental Neurology
  60. Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
    Gabriel C. Léger, Fadi Massoud · 2013 · Expert Review of Clinical Pharmacology
  61. Peptide Vaccines for Hypertension and Diabetes Mellitus
    Hironori Nakagami, Hiroshi Koriyama, Ryuichi Morishita · 2014 · Vaccines
  62. Monitoring the amyloid beta-peptide in vivo – caveat emptor
    Paul W. Thompson, Andrew Lockhart · 2009 · Drug Discovery Today
  63. Nonhuman Amyloid Oligomer Epitope Reduces Alzheimer’s-Like Neuropathology in 3xTg-AD Transgenic Mice
    Suhail Rasool, Hilda Martínez‐Coria, Saskia C. F. Milton, Charles G. Glabe · 2013 · Molecular Neurobiology
  64. Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
    Meaghan C. Creed, Norton William Milgram · 2010 · AGE
  65. Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy
    Noel J. Byrne, Amy C. Lee, James C. Kostas, John C. Reid, Andrea T. Partridge, Sung‐Sau So, Joseph E. Cowan, Pravien D. Abeywickrema, Hua Huang, Matthias Zebisch et al. · 2020 · Protein Expression and Purification
  66. Anti‐amyloid precursor protein immunoglobulins inhibit amyloid‐β production by steric hindrance
    Rhian S. Thomas, J. Eryl Liddell, Emma J. Kidd · 2010 · FEBS Journal
  67. Immune Responses to Herpesviral Vectors
    Deborah A. Ryan, Howard J. Federoff · 2009 · Human Gene Therapy
  68. Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer’s Disease Status and Risk Genotype
    Erica Lana, Anna Gellerbring, Sabrina Jung, Agneta K. Nordberg, Christina Unger Lithner, Taher Darreh‐Shori · 2019 · Frontiers in Molecular Neuroscience
  69. Immunotherapy for Alzheimer's Disease and Other Dementias
    Delphine Boche, James A. R. Nicoll, Roy O. Weller · 2006 · Clinical Neuropharmacology
  70. Tangles precede plaques but don?t cause them
    Robert D. Terry · 2004 · Neurobiology of Aging
  71. The Primary Care of Alzheimer Disease
    Craig D. Rubin · 2006 · The American Journal of the Medical Sciences
  72. 40 Hz acoustic stimulation decreases amyloid beta and modulates brain rhythms in a mouse model of Alzheimer’s disease
    Juho Lee, Seungjun Ryu, Hyun-Ju Kim, Jieun Jung, Boreom Lee, Tae Kim · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  73. Detangling Alzheimer's Disease
    Laura L. Helmuth · 2003 · Science of Aging Knowledge Environment
  74. Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
    Marta Westwood, Alastair D. G. Lawson · 2015 · Antibodies
  75. Amyloid β peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid β burden in an Alzheimer’s disease mouse model
    Jun-ichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki · 2009 · Biochemical and Biophysical Research Communications
  76. Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response
    Ying Ma, Li Yu, Lixia Zong, Xiaona Xing, Weige Zhang, Yunpeng Cao · 2011 · Brain Research
  77. Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
    Satoshi Saitô, Kaori Shinmyozu, Daisuke Kawakami, Miho Yamauchi, Shuhei Ikeda, Yorito Hattori, Rintaro Yamamoto, Naoki Hayakawa, Masafumi Ihara · 2021 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  78. Alzheimer's Factors in Ischemic Brain Injury
    Ryszard M. Pluta, Mirosaw Jaboski · 2012 · InTech eBooks
  79. Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
    Rakez Kayed, George R. Jackson, D. Mark Estes, Alan D.T. Barrett · 2011 · Journal of Central Nervous System Disease
  80. Immune-Directed Gene Therapeutic Development for Alzheimer’s, Prion, and Parkinson’s Diseases
    Kathleen A. Maguire‐Zeiss, Howard J. Federoff · 2008 · Journal of Neuroimmune Pharmacology
  81. When should drug treatment be started for people with dementia?
    Baldev Singh, John Tiernan O'Brien · 2009 · Maturitas
  82. Low Concentrations of Anti-Aβ Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology
    Nina Movsesyan, Hayk Davtyan, Mikayel Mkrtichyan, Irina Petrushina, Tigran Tiraturyan, Ted M. Ross, Michael G. Agadjanyan, Anahit Ghochikyan, David H. Cribbs · 2010 · Human Gene Therapy
  83. An Aβ3-10-KLH vaccine reduced Alzheimer’s disease-like pathology and had a sustained effect in Tg-APPswe/PSEN1dE9 mice
    Yuan Meng, Li Ding, Huiyi Zhang, Wenchao Yin, Yi Yan, Yunpeng Cao · 2017 · Brain Research
  84. Attack on amyloid
    Philipp J. Kahle, Bart De Strooper · 2003 · EMBO Reports
  85. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer’s patients: An interobserver study
    Roland M. Martens, Arianne Bechten, Silvia Ingala, Ronald A. van Schijndel, Vania B. Machado, Marcus C. de Jong, Esther Sánchez, Derk D. Purcell, Michael Arrighi, Robert H. Brashear et al. · 2017 · European Radiology
  86. Alzheimer’s Disease and Dementia
    Patrick Alfryn Lewis, Jennifer E. Spillane · 2018 · Elsevier eBooks
  87. Is amyloid-β-peptide immunization clinically effective in patients with Alzheimer's disease?
    Thomas Wısnıewskı · 2005 · Nature Clinical Practice Neurology
  88. Diagnosis, pathomechanisms and therapy of cerebral amyloid angiopathy-related inflammation (CAA-ri)
    Rebecca M. Seifert, Randolf Klingebiel, Wolf‐Rüdiger Schäbitz · 2025 · Neurological Research and Practice
  89. Receptor-based approaches and therapeutic targets in Alzheimer’s disease along with role of AI in drug designing: Unraveling pathologies and advancing treatment strategies
    Mohsina Patwekar, Faheem Patwekar, Daniyal Shaikh, Shaikh Rohin Fatema, Sunil J. Aher, Rohit Sharma · 2023 · Applied Chemical Engineering
  90. Adverse effects of a SOD1-peptide immunotherapy on SOD1G93A mouse slow model of amyotrophic lateral sclerosis
    Javier Sábado, Anna Casanovas, Hess Michelini Rodrigo, Glòria Arqué, Josep Enric Esquerda · 2015 · Neuroscience
  91. Therapeutic applications of antibodies in non-infectious neurodegenerative diseases
    Pavan Krishnamurthy, Einar M. Sigurdsson · 2011 · New Biotechnology
  92. Efficacy and Safety of the Immunization with DNA for Alzheimer’s Disease in Animal Models: A Systematic Review from Literature
    Yandara Akamine Martins, Cristiane Jumko Tsuchida, Patrícia Antoniassi, Izabel Galhardo Demarchi · 2017 · Journal of Alzheimer s Disease Reports
  93. Recent Trends in Microneedle Development & Applications in Medicine and Cosmetics (2013–2018)
    Jaspreet Singh Kochhar, Justin Tan, Yee Chin Kwang, Lifeng Kang · 2019 · Springer eBooks
  94. Acquired immunity and Alzheimer's disease
    Weixi Feng, Yanli Zhang, Peng Gang Sun, Ming Xiao · 2022 · Journal of Biomedical Research
  95. Clinical immunotherapy trials in Alzheimer’s disease
    Cheryl A. Hawkes, JoAnne McLaurin · 2008 · Drug Discovery Today Therapeutic Strategies
  96. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines
    Hayk Davtyan, Anahit Ghochikyan, Armine Hovakimyan, Irina Petrushina, Jianmei Yu, David C. Flyer, Peter Juul Madsen, Lars Østergaard Pedersen, David H. Cribbs, Michael G. Agadjanyan · 2014 · Journal of Neuroimmunology
  97. Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem
    David Henry Small, Dušan Lošić, Lisandra L. Martin, Bradley J. Turner, Anna M. Friedhuber, Marie‐Isabel Aguilar · 2004 · IUBMB Life
  98. Immunotherapeutic relief from persistent infections and amyloid disorders
    Dorian B. McGavern · 2006 · Neurology
  99. Treatment and prevention of the amyloidoses
    Joel N. Buxbaum · 2006 · Neurology
  100. Research into neurodegenerative disease: an entangled web of mice and men
    Toshiki Uchihara, Werner Paulus · 2007 · Acta Neuropathologica